Shreeram Aradhye, Novartis’s Global Head, Medical Affairs, and Chief Medical Officer (Pharmaceuticals), is upbeat about the company’s pipeline for debilitating diseases like multiple sclerosis, including the investigational asset ofatumumab, which he believes has the potential to offer “B cell therapy 2.0” in MS. Aradhye had earlier played a pivotal role for Gilenya (fingolimod) as its Senior Global Program Medical Director.
In an exclusive interview with Scrip on the side lines of BioAsia 2018 in Hyderabad recently, Aradhye also shared insights into how the Swiss multinational is piloting efforts using artificial intelligence and machine learning in areas like clinical trials